rs587776949 — NDUFS4

NDUFS4 c.462delA — A Mitochondrial Complex I Frameshift with Leigh Syndrome Risk

Mitochondrial complex I (NADH:ubiquinone oxidoreductase¹¹ NADH:ubiquinone oxidoreductase
The largest enzyme in the mitochondrial respiratory chain, comprising 45 subunits, 14 of which form the catalytic core. It transfers electrons from NADH to ubiquinone, pumping protons to drive ATP synthesis) is the cell's primary engine for converting food into energy. The NDUFS4 subunit is a nuclear-encoded accessory subunit²² nuclear-encoded accessory subunit
NDUFS4 is encoded in the nuclear genome and imported into the mitochondrial matrix; it stabilizes the final assembly of the complex I holocomplex and carries a cAMP-dependent phosphorylation site that regulates enzyme activation required for complete complex I assembly and activation. The c.462delA frameshift — a single adenine deletion at position 462 in the coding sequence — disrupts the reading frame at codon 154, producing a truncated protein (p.Lys154fs) that lacks the phosphorylation site essential for complex I activation.

Among Ashkenazi Jewish families, this variant has been identified as a founder mutation³³ founder mutation
A mutation present in high frequency in a specific population due to descent from a small number of founders who carried the variant; the AJ population has experienced several well-characterized founder effects for recessive disease alleles with a carrier frequency of approximately 1 in 1,000. For most carriers, the other copy of NDUFS4 is intact and complex I function is entirely normal. The risk materializes only when both parents are carriers, giving each child a 25% chance of inheriting two deletion alleles and developing Leigh syndrome.

The Mechanism

The c.462delA deletion shifts the reading frame after codon 154, replacing the final 22 amino acids of NDUFS4 with a novel sequence before encountering a premature stop codon. The resulting truncated protein cannot serve its normal role in complex I holocomplex stabilization⁴⁴ complex I holocomplex stabilization
NDUFS4 is incorporated in one of the last steps of complex I assembly. Without functional NDUFS4, the 550-kilodalton membrane-arm complex assembles but remains unstable and is present at sharply reduced levels. The critical phosphorylation site for cAMP-dependent kinase activation is also absent, further impairing the enzyme's ability to respond to cellular energy signals.

Homozygous loss of NDUFS4 therefore creates a state of severe mitochondrial energy deficiency. Neurons — which depend almost entirely on oxidative phosphorylation — are the most vulnerable cell type. In the Ndufs4 knockout mouse model, glutamatergic neurons mediate most of the motor and respiratory phenotype⁵⁵ glutamatergic neurons mediate most of the motor and respiratory phenotype
Single-cell studies show Vglut2-expressing glutamatergic neurons in the brainstem die earliest; GABAergic neurons contribute later through inflammation and epilepsy, while activated microglia drive a secondary neuroinflammatory cascade involving NLRP3 inflammasome and IL-6⁶⁶ NLRP3 inflammasome and IL-6
Elevated NLRP3 and IL-6 pro-inflammatory pathways were confirmed in NDUFS4-mutant iPSC-derived brain organoids and postmortem Leigh syndrome tissue from human patients that amplifies neuronal death.

The Evidence

The clinical significance of biallelic NDUFS4 loss is unambiguous. Leigh syndrome (subacute necrotizing encephalomyelopathy) caused by NDUFS4 mutations presents in infancy or early childhood with developmental regression, hypotonia, feeding difficulties, respiratory failure, and characteristic bilateral symmetric lesions in the basal ganglia and brainstem on MRI. The course is typically progressive and often fatal within the first years of life⁷⁷ often fatal within the first years of life
Published case series document death from respiratory failure, usually before age 5, in most NDUFS4-null children; some survive longer with intensive supportive care.

Anderson et al. 2008⁸⁸ Anderson et al. 2008
Journal of Inherited Metabolic Disease, December 2008 (PMID 19107570) identified c.462delA as the causal mutation in three affected children from a non-consanguineous Ashkenazi Jewish family. Screening of 5,000 healthy AJ individuals revealed a carrier frequency of approximately 1 in 1,000, leading the authors to recommend that this variant should be evaluated in all AJ patients presenting with Leigh syndrome before proceeding to more extensive enzyme studies.

Leshinsky-Silver et al. 2009⁹⁹ Leshinsky-Silver et al. 2009
Molecular Genetics and Metabolism, July 2009 (PMID 19364667) confirmed p.Lys154fs in a second patient — a compound heterozygote carrying the AJ founder allele alongside a novel NDUFS4 missense — with Leigh syndrome showing predominant brainstem involvement and fatal outcome in early childhood. Together these reports establish the biological mechanism, the Ashkenazi Jewish population risk, and the clinical phenotype.

Practical Actions

For confirmed carriers (DI genotype), the finding has no impact on personal health — complex I activity is entirely normal with one functional allele. The clinical relevance is reproductive: if a carrier has a child with a partner who is also a carrier, each pregnancy has a 25% risk of Leigh syndrome.

Carrier screening for the Ashkenazi Jewish population panel should include NDUFS4 c.462delA. Several expanded carrier screening programs include it explicitly. For carriers planning a family, preconception genetic counseling can guide decisions about preimplantation genetic testing (PGT) or prenatal diagnosis.

For the rare homozygous individual, management is supportive and ideally coordinated by a specialized mitochondrial disease center. Treatments under investigation in animal models include rapamycin (mTOR inhibition to reduce cellular energy demand) and ketogenic diet (providing an alternative fuel source that bypasses the complex I block). Microglial ablation has extended lifespan in mouse models by reducing neuroinflammation. None of these are established clinical protocols, but referral to a mitochondrial disease specialist ensures access to current evidence and any available clinical trials.

Interactions

As an autosomal recessive condition, the key interaction is the combination of two heterozygous NDUFS4 c.462delA carriers producing a homozygous child. This is documented as a Mendelian transmission pattern, not a genetic interaction in the complex-I-pathway sense. There are no documented gene-gene interactions between NDUFS4 c.462delA and other nuclear-encoded complex I subunit variants in terms of modifying carrier status — two heterozygous carriers of different NDUFS4 pathogenic alleles could produce a compound heterozygous affected child, which is biologically equivalent to homozygosity in terms of complex I loss.